Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alvalin (cathine hydrochloride) versus placebo in obese patients (BMI 30–45 kg/m²)
2012-003426-24Phase 3Completed
- Sponsor
- RIEMSER
- Start
- Oct 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in obesity comparing Alvalin (cathine hydrochloride) with Placebo (2 arms). Primary endpoints: Primary weight loss endpoint and Primary composite success criterion. Started Oct 2012; status: completed.
02
Drugs
cathine
03
Conditions
obesity
Beyond the preview
Go deeper on 2012-003426-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-003426-24.